公开(公告)号：US20070015720A1

公开(公告)日：2007-01-18

申请号：US11347811

申请日：2006-02-03

申请人： Karen Bulock ,  Mark Tepper ,  John Zhang ,  Roustem Nabioullin

发明人： Karen Bulock ,  Mark Tepper ,  John Zhang ,  Roustem Nabioullin

IPC分类号： A61K31/7056

CPC分类号： C12N15/1137 ,  A61K31/7056 ,  C12N2310/14 ,  C12Y201/02003

摘要： The invention relates to methods for treating type 2 diabetes, obesity, metabolic syndrome and conditions associated with these by administering an AICAR-monophosphate (AICAR-MP) enhancing agent that increases endogenous AICAR-MP levels in a cell. Inhibition of AICAR-formyltransferase activity (AICARFT) in a cell that regulates metabolic activity (such as fat, liver, muscle, pancreatic beta or certain brain cells) increases AICAR-monophosphate levels which in turn results in activation of the AMP-kinase (AMPK) pathway, and all of the downstream functions mediated by AMPK including increased fatty acid oxidation, enhanced glucose transport and decreased fatty acid synthesis.

摘要翻译： 本发明涉及通过施用增加细胞内源性AICAR-MP水平的AICAR-一磷酸（AICAR-MP）增强剂治疗2型糖尿病，肥胖症，代谢综合征和与此相关的病症的方法。 在调节代谢活性的细胞（如脂肪，肝脏，肌肉，胰腺β或某些脑细胞）中抑制AICAR-甲酰转移酶活性（AICARFT）增加AICAR-单磷酸盐水平，这反过来导致AMP-激酶（AMPK ）途径，并且由AMPK介导的所有下游功能包括增加的脂肪酸氧化，增强的葡萄糖转运和降低的脂肪酸合成。